HC Wainwright & Co. Reiterates Buy on OKYO Pharma, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for OKYO Pharma, maintaining a price target of $7. Analyst Yi Chen continues to support the stock, indicating confidence in its potential growth.
October 16, 2024 | 6:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for OKYO Pharma, maintaining a price target of $7. Analyst Yi Chen continues to support the stock, indicating confidence in its potential growth.
The reiteration of a Buy rating and maintenance of a $7 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100